| (210) | Number of the EPO application | 17818406 |
| (220) | Filing date of the EPO application | 2017.12.07 |
| (80) | EPO patent specification publication (B) | EPB nr. 37/2023, 2023.09.13 |
| (110) | EPO patent number | 3551660 |
| (11) | Number of the document | MD 3551660 T2 |
| (21) | Number of the application | e 2019 1162 |
| (71) | Name(s) of applicant(s), code of the country | AGENUS INC., US;
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, CH;
MEMORIAL SLOAN KETTERING CANCER CENTER, US; |
| (72) | Name(s) of inventor(s), code of the country | VAN DIJK Marc, NL;
MUNDT Cornelia Anne, DE;
RITTER Gerd, US;
SCHAER David, US;
WOLCHOK Jedd David, US;
MERGHOUB Taha, US;
WILSON Nicholas Stuart, US;
SAVITSKY David Adam, US;
FINDEIS Mark Arthur, US;
UNDERWOOD Dennis John, US;
CUILLEROT Jean-Marie, US;
PROSCURSHIM Igor, US;
SHEBANOVA Olga, US; |
| (73) | Name(s) of owner(s), code of the country | AGENUS INC., US;
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, CH;
MEMORIAL SLOAN KETTERING CANCER CENTER, US; |
| (54) | Title of the invention | Anti-CTLA-4 antibodies and methods of use thereof |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07K 16/28 (2006.01.01); A61K 39/00 (2006.01.01); A61P 11/00 (2006.01.01); A61P 35/04 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.11.30 |
| (49) | Date of publication of the translation of the validated European patent specification | 2024.03.31 |
| (30) | Priority | 201662431272 P, 2016.12.07, US |
| (74) | Patent attorney | (Procedură) SOCOLOVA Sofia, Str. Drumul Viilor nr. 42, bloc 3, ap. 60, MD-2021, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2017/065011, 2017.12.07 |
| (87) | International publication | WO 2018/106862, 2018.06.14 |